Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Abstract | OBJECTIVE: METHOD: CATIE-AD included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo. Based on their clinicians' judgment, patients could discontinue the originally assigned medication and receive another randomly assigned medication. Patients were followed for 36 weeks, and cognitive assessments were obtained at baseline and at 12, 24, and 36 weeks. Outcomes were compared for 357 patients for whom data were available for at least one cognitive measure at baseline and one follow-up assessment that took place after they had been on their prescribed medication or placebo for at least 2 weeks. RESULTS: Overall, patients showed steady, significant declines over time in most cognitive areas, including in scores on the Mini-Mental State Examination (MMSE; -2.4 points over 36 weeks) and the cognitive subscale of the Alzheimer's Disease Assessment Scale (-4.4 points). Cognitive function declined more in patients receiving antipsychotics than in those given placebo on multiple cognitive measures, including the MMSE, the cognitive subscale of the Brief Psychiatric Rating Scale, and a cognitive summary score summarizing change on 18 cognitive tests. CONCLUSIONS:
|
Authors | Cheryl L P Vigen, Wendy J Mack, Richard S E Keefe, Mary Sano, David L Sultzer, T Scott Stroup, Karen S Dagerman, John K Hsiao, Barry D Lebowitz, Constantine G Lyketsos, Pierre N Tariot, Ling Zheng, Lon S Schneider |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 168
Issue 8
Pg. 831-9
(Aug 2011)
ISSN: 1535-7228 [Electronic] United States |
PMID | 21572163
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antipsychotic Agents
- Dibenzothiazepines
- Benzodiazepines
- Quetiapine Fumarate
- Risperidone
- Olanzapine
|
Topics |
- Activities of Daily Living
(classification, psychology)
- Aged
- Aged, 80 and over
- Alzheimer Disease
(diagnosis, drug therapy, psychology)
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
(adverse effects, therapeutic use)
- Cognition Disorders
(chemically induced, diagnosis, drug therapy, psychology)
- Dibenzothiazepines
(adverse effects, therapeutic use)
- Disease Progression
- Double-Blind Method
- Drug Substitution
- Female
- Follow-Up Studies
- Humans
- Male
- Mental Status Schedule
(statistics & numerical data)
- Neuropsychological Tests
(statistics & numerical data)
- Olanzapine
- Patient Dropouts
(statistics & numerical data)
- Quetiapine Fumarate
- Risperidone
(adverse effects, therapeutic use)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|